Results 141 to 150 of about 2,075,366 (204)

Two types amyloid infiltration of the heart: diagnostic challenges and therapeutic strategies. [PDF]

Cardiooncology
Ramos-Polo R, Jiménez-Marrero S, Morillas H, Pons-Riverola A, Garay A, Carro I, Gràcia LM, Baixeras N, Sánchez-Vega J, Moliner P.   +9 more
europepmc   +1 more source

Real-world effectiveness of targeted therapies in ATTR cardiomyopathy: A meta-analysis integrating population-based data. [PDF]

ESC Heart Fail
Antonopoulos AS, Tsampras T, Terentes-Printzios D, Lazaros G, Tsioufis K, Vlachopoulos C.   +5 more
europepmc   +1 more source

A Comprehensive Review of the Management of Light-Chain (AL) and Transthyretin (ATTR) Cardiac Amyloidosis. [PDF]

Rev Cardiovasc Med
Alkhatib A, Alashqar R, Abdallah AW, Abu-Nejim H, Hammad A, Khraisat O, Abuzaid AS.   +6 more
europepmc   +1 more source

The phenotypic landscape of p.Ala117Ser transthyretin amyloidosis: distinct clinical profiles and outcomes versus wild-type ATTR. [PDF]

BMC Cardiovasc Disord
Tuntiwongkosee P, Kochaiyapatana P, Phowthongkum P, Amornvit J, Saicharoen K, Chattranukulchai P, Chettakulanurak K, Puwanant S.   +7 more
europepmc   +1 more source

Sex-specific differences in cardiac transthyretin amyloidosis: addressing the diagnostic gap in women. [PDF]

Eur Heart J Open
Vogel J, Jura S, Settelmeier S, Lerchner T, Buehning F, Yahsaly L, Carpinteiro A, Reinhardt HC, Rassaf T, Michel L.   +9 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

SGLT2i effects depending on functional capacity in ATTR-CM

European Journal of Preventive Cardiology
Abstract Introduction Heart failure (HF) with exercise intolerance is a common symptom of transthyretin amyloid cardiomyopathy (ATTR-CM), often initially presenting with preserved ejection fraction that deteriorates over time.
B Gregshammer, R Willixhofer, N Ermolaev, M Eslami, R Badr-Eslam   +4 more
openaire   +2 more sources

NT-proBNP and cardiopulmonary exercise testing parameters for risk stratification in ATTR-CM

European Journal of Preventive Cardiology
Abstract Introduction Transthyretin amyloid cardiomyopathy (ATTR-CM) is an infiltrative storage disease that typically leads to congestive heart failure (HF) and is accompanied by an elevated cardiac biomarker as N-terminal pro B-type natriuretic peptide (NT-proBNP).
B Gregshammer, R Willixhofer, N Ermolaev, R Badr-Eslam   +3 more
openaire   +2 more sources

Silence Disease Progression With Early Treatment of ATTR-CM

Journal of the American College of Cardiology
Joban, Vaishnav, Brett W, Sperry
openaire   +3 more sources